AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Replimune Group Inc. (REPL)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

14.32

0.54 (3.92%)

At close: Feb 20, 2025, 3:59 PM

14.75

3.00%

After-hours: Feb 20, 2025, 06:57 PM EST

undefined% (undefined)

Bid	14.5
Market Cap	1.10B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-3.07
PE Ratio (ttm)	-4.66
Forward PE	n/a
Analyst	Buy

Ask	14.95
Volume	894,345
Avg. Volume (20D)	907,264
Open	13.72
Previous Close	13.78
Day's Range	13.42 - 14.78
52-Week Range	4.92 - 17.00
Beta	undefined

About REPL

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Pha...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 20, 2018

Employees 331

Stock Exchange NASDAQ

Ticker Symbol REPL

Website https://www.replimune.com

Full Company Profile

Analyst Forecast

According to 6 analyst ratings, the average rating for REPL stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 25.70% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

4 weeks ago

+9.87%

Replimune Group shares are trading higher after HC... Unlock content with Pro Subscription

1 month ago

+16.86%

Replimune Group shares are trading higher after the company announced the FDA has accepted the biologics license application for RP1 in combination with nivolumab for patients with advanced melanoma

News

1 week ago · seekingalpha.com

Replimune: A Misunderstood Contender In Oncolytics

Replimune Group's solid cash position and strategic focus on niche oncology markets position it for potential success, despite market volatility and past trial setbacks. The company's RP1 and RP2 plat...

4 weeks ago · zacks.com

REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA

The FDA accepts and grants priority review to Replimune's BLA for RP1 in combination with Opdivo for advanced melanoma. A decision is due on July 22, 2025.

2 months ago · seekingalpha.com

Replimune: RPL1 BLA Submission Under AA Pathway Makes It A Must Watch

Replimune has submitted its BLA of RP1 + Opdivo for the treatment of advanced melanoma patients previously treated with an anti-PD1 containing regimen. The phase 3 confirmatory IGNYTE-3 study is under...

3 months ago · zacks.com

Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug

REPL stock soars after submitting a BLA to the FDA seeking accelerated approval for its lead candidate, RP1, in combination with Opdivo for advanced melanoma.